WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Agrisoma Biosciences Inc.
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Webinar
Industrial Impact
Thermo Fisher Scientific Inc. | August 23, 2022
Thermo Fisher Scientific Inc., the world leader in serving science, opened its largest single-use technology manufacturing site in Greater Nashville. The $105 million, 400,000-square-foot facility enables the company to help meet rapidly growing demand for the bioprocessing materials needed to produce vaccines and breakthrough therapies for cancer and other diseases. This new site is part of Thermo Fisher’s $650 million multi-year investment to expand its bioprocessing production cap...
MedTech, AI
Businesswire | August 18, 2023
FOXO Technologies Inc. a leader in the field of commercializing epigenetic biomarker technology, has advanced in its mission to utilize the power of epigenetics and artificial intelligence to generate data-driven insights that promote optimal health and longevity. In collaboration with DataRobot, the leader in Value-Driven AI, FOXO has successfully harnessed the powers of predictive AI and high-throughput automation to estimate factors associated with human longevity using epigenetic bioma...
Amyris, Inc. | January 25, 2022
Amyris, Inc. a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ operating platform announces that it has agreed to exclusive terms to acquire the assets of MenoLabs, LLC, a women-founded company to treat menopause symptoms, drive research for women's health and improve society's understanding of menopause. Amyris previously communicated its intention of launching a new consumer...
iNtRON Biotechnology | July 12, 2022
iNtRON Biotechnology announced that CDL200, a novel biological drug candidate under the development of the world's first enteric colon-targeted capsule formulation for the treatment of intractable and recurrent CDI confirmed the strong efficacy against clinical isolates from CDI patients. A company official explained that the antibacterial activity of CDL200 was evaluated for 20 clinical isolates from patients in Europe and Korea, and rapid lysis effect within few minutes afte...
Medical
Video
Whitepaper
Cell and Gene Therapy, Medical
MedTech
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE